Alternatives to Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Look Back at the State of the Field in 2012

References

• . Knecht S, Wilton SB, Haïssaguerre M. The 2010 update of the ESC guidelines for the management of atrial fibrillation. Circ J. 2010;74(12):2534–2537
   PubMedGoogle Scholar
• . Al-Khatib SM, Alexander JH, Lopes RD, Mahaffey KW, Patel MR, Granger CB. Promise of factor Xa inhibition in atrial fibrillation. Curr Cardiol Rep. 2012;14(1):70–78
   PubMedGoogle Scholar
• . Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J Thromb Haemost. 2011;9( suppl 1):344–351
   PubMed Web of Science ®Google Scholar
• . Singh SN, Tang XC, Singh BN, ; SAFE-T Investigators. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy J Am Coll Cardiol. 2006;48(4):721–730
   PubMedGoogle Scholar
• . Camm AJ, Kirchhof P, Lip GY; . European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429
   PubMed Web of Science ®Google Scholar
• . Roger VL, Go AS, Lloyd-Jones DM, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18–e209
   PubMed Web of Science ®Google Scholar
• . Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988
   PubMed Web of Science ®Google Scholar
• . Lopes RD, Shah BR, Olson DM, . Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the AVAIL Registry. Stroke. 2011;42(12):3477–3483
   PubMed Web of Science ®Google Scholar
• . Wang TJ, Massaro JM, Levy D, . A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290(8):1049–1056
   PubMed Web of Science ®Google Scholar
• . Piccini JP, Lopes RD, Mahaffey KW. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol. 2010;25(4):312–320
   PubMed Web of Science ®Google Scholar
• . Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870
   PubMed Web of Science ®Google Scholar
• . Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272
   PubMed Web of Science ®Google Scholar
• . Wasmer K, Eckardt L. Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. Europace. 2011;13(10):1368–1374
   PubMedGoogle Scholar
• . Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED)to assess 1-year risk of major bleeding inpatients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100
   PubMed Web of Science ®Google Scholar
• . Clayville LR, Anderson KV, Miller SA, St Onge EL. New options in anticoagulation for the prevention of venous thromboembolism and stroke. P T. 2011;36(2):86–99
   PubMedGoogle Scholar
• . Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175–179
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18(2):349–355
   PubMedGoogle Scholar
• . Ezekowitz MD, Bridgers SL, James KE, . Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327(20):1406–1412
   PubMed Web of Science ®Google Scholar
• . The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323(22):1505–1511
   PubMedGoogle Scholar
• . Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991;84(2):527–539
   PubMed Web of Science ®Google Scholar
• . Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492–501
   PubMed Web of Science ®Google Scholar
• . Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867
   PubMed Web of Science ®Google Scholar
• . Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation. 2012;125(1):159–164
   PubMed Web of Science ®Google Scholar
• . Holbrook AM, Pereira JA, Labiris R, . Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–1106
   PubMed Web of Science ®Google Scholar
• . Jowett S, Bryan S, Mant J, . Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. Stroke. 2011;42(6):1717–1721
   PubMed Web of Science ®Google Scholar
• . Gage BF, Boechler M, Doggette AL, . Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31(4):822–827
   PubMed Web of Science ®Google Scholar
• . Albers GW, Yim JM, Belew KM, . Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996;156(20):2311–2316
   PubMedGoogle Scholar
• . Piccini JP, Hernandez AF, Zhao X, ; Get With The Guidelines Steering Committee and Hospitals. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009;54(14):1280–1289
   PubMed Web of Science ®Google Scholar
• . Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37(4):1070–1074
   PubMed Web of Science ®Google Scholar
• . Lopes RD, Elliott LE, White HD, . Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009;30(16):2019–2028
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7(4):281–287
   PubMedGoogle Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–1876
   PubMed Web of Science ®Google Scholar
• . Healey JS, Eikelboom J, Douketis J, ; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126(3):343–348
   PubMed Web of Science ®Google Scholar
• . Wann LS, Curtis AB, Ellenbogen KA, . 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;57(11):1330–1337
   PubMed Web of Science ®Google Scholar
• . Eikelboom JW, Wallentin L, Connolly SJ, . Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372
   PubMed Web of Science ®Google Scholar
• . Diener HC, Connolly SJ, Ezekowitz MD, ; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157–1163
   PubMed Web of Science ®Google Scholar
• . Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562–2570
   PubMed Web of Science ®Google Scholar
• . Freeman JV, Zhu RP, Owens DK, . Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1–11
   PubMed Web of Science ®Google Scholar
• . Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012;43(3):881–883
   PubMed Web of Science ®Google Scholar
• . Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm. 2008;65(16):1520–1529
   PubMed Web of Science ®Google Scholar
• . Kubitza D, Becka M, Mueck W, . Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703–712
   PubMed Web of Science ®Google Scholar
• . Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891
   PubMed Web of Science ®Google Scholar
• . Hankey GJ, Patel MR, Stevens SR, ; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315–322
   PubMed Web of Science ®Google Scholar
• . Fox KA, Piccini JP, Wojdyla D, . Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–2394
   PubMed Web of Science ®Google Scholar
• . Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110(6):845–851
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Ann Rev Med. 2011;62:41–57
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, . Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817
   PubMed Web of Science ®Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992
   PubMed Web of Science ®Google Scholar
• . Easton JD, Lopes RD, Bahit MC, . ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503–511
   PubMed Web of Science ®Google Scholar
• . Hohnloser SH, Hijazi Z, Thomas L, . Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821–2830
   PubMed Web of Science ®Google Scholar
• . Lopes RD, Al-Khatib SM, Wallentin L, . Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012;380(9855):1749–1758
   PubMedGoogle Scholar
• . Oldgren J, Alings M, Darius H, ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155(10):660–667
   PubMed Web of Science ®Google Scholar
• . Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes. 2012;5(4):472–479
   PubMed Web of Science ®Google Scholar
• . Lee S, Mullin R, Blazawski J, Coleman CI. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One. 2012;7(10):e47473
   Google Scholar
• . Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology. 2012;79(14):1428–1434
   PubMed Web of Science ®Google Scholar
• . Ogata K, Mendell-Harary J, Tachibana M, . Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–753
   PubMed Web of Science ®Google Scholar
• . Ruff CT, Giugliano RP, Antman EM, . Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–641
   PubMed Web of Science ®Google Scholar